BCRX (BioCryst Pharmaceuticals) Marketable Securities: $66.8 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BCRX BioCryst Pharmaceuticals Inc BCRX
67 GF Score
Price $9.30
GF Value $12.45
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BioCryst Pharmaceuticals Marketable Securities?

BioCryst Pharmaceuticals BCRX -4.42% 67 Marketable Securities is $66.8 Mil as of Mar. 2026. GuruFocus rates BCRX with a GF Score™ of 67/100 and a GF Value™ of $12.45 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. BioCryst Pharmaceuticals's Marketable Securities for the quarter that ended in Mar. 2026 was $66.8 Mil.

BioCryst Pharmaceuticals's annual Marketable Securities declined from Dec. 2023 ($278.3 Mil) to Dec. 2024 ($216.1 Mil) and declined from Dec. 2024 ($216.1 Mil) to Dec. 2025 ($185.0 Mil).

BioCryst Pharmaceuticals  (NAS:BCRX) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

BioCryst Pharmaceuticals Marketable Securities Related Terms

BioCryst Pharmaceuticals Marketable Securities Historical Data

* Premium members only.

The historical data trend for BioCryst Pharmaceuticals's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioCryst Pharmaceuticals Marketable Securities Chart

BioCryst Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.21 119.54 278.34 216.14 185.01

BioCryst Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 189.90 172.01 128.80 185.01 66.81
BCRX
67GF Score
BioCryst Pharmaceuticals Inc BCRX
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioCryst Pharmaceuticals Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $66.8 Mil mean?
BioCryst Pharmaceuticals (BCRX) has a Marketable Securities of $66.8 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on BioCryst Pharmaceuticals and its competitors.
Is BioCryst Pharmaceuticals' Marketable Securities too high?
BioCryst Pharmaceuticals' current Marketable Securities is $66.8 Mil. Overall, BioCryst Pharmaceuticals has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioCryst Pharmaceuticals' Marketable Securities compare to SUPN and PBH?
BioCryst Pharmaceuticals' Marketable Securities of $66.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on BioCryst Pharmaceuticals and its competitors. BioCryst Pharmaceuticals's current Marketable Securities is $66.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCryst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals (BCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $12.45, compared to a current price of $9.30 — trading 25.3% below its estimated fair value. The current Marketable Securities is $66.8 Mil. BioCryst Pharmaceuticals' overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For BioCryst Pharmaceuticals (BCRX), the current Marketable Securities is $66.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioCryst Pharmaceuticals (BCRX) Overvalued in 2026?

Based on GuruFocus' analysis, BioCryst Pharmaceuticals stock appears to be undervalued. The current stock price of $9.30 is trading 25.3% below its estimated GF Value™ of $12.45. GuruFocus considers BioCryst Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for BCRX:

  • Marketable Securities: $66.8 Mil
  • GF Value™: $12.45 vs. price of $9.30 (25.3% below fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the BCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioCryst Pharmaceuticals Business Description

Other Exchanges BCRX:MexicoBO1:Germany
Address 4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
67GF Score

Get the complete analysis for BCRX

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.30
Price
$12.45
GF Value